Re-bound at full text: 65 records name CXCR4 and a menin inhibitor in the same document and the 50 read are all reviews of AML therapy - no study measures the CXCR4 axis under menin inhibition
also called Q115 CXCR4 re-bound
Nobody has measured what the menin drug does to the signal that keeps leukaemia cells anchored in the bone marrow. Searching whole papers finds sixty-five documents that mention both, and every one read is a review article listing treatments.
The same thing, for a scientist
`absence-cxcr4-axis-never-measured-under-menin-inhibition` was already re-run at abstract level in cycle 65 and survived twice with clean querytranslations. Re-run at full text: `BODY:"CXCR4"` crossed with a 20-name menin-inhibitor list returns **65**, widening the receptor clause to `CXCR4 OR CXCL12 OR SDF-1` returns **69**, against an operand of 68,559 for CXCR4 alone [E1]. **Fifty were read. Two are congress abstract books and the other forty-eight are review articles** - *Integrating Targeted Therapies into AML Frontline Therapy*, *Resistance to Targeted Therapy in AML*, *Mechanisms of Resistance to Small Molecules in AML*, *Emerging and Future Targeted Therapies for Pediatric AML: Targeting the Leukemia Stem Cells*, and so on - each naming CXCR4 in a microenvironment paragraph and a menin inhibitor in a therapy paragraph [E1]. **No measurement. The absence survives, and the widening from 0 at abstract level to 65 at full text is entirely review literature.** One record is a primary paper worth naming: **PMID 41743263** (*HemaSphere* 2026), *Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups* - the right disease and the right question shape, title-checked only [E1].
| script | none - Europe PMC BODY: queries, 2026-09-22 |
|---|---|
| status | run |
| verdict | SURVIVES at full text, having already survived twice at abstract level in cycle 65 |
| entry re bounded | absence-cxcr4-axis-never-measured-under-menin-inhibition |
| absence class | measured-not-analysed |
| absence class basis | UNCHANGED from the entry under test. Nothing in this re-bound changes the archive position; the literature instrument moves from abstract level to full text. |
queries — the numbers behind the chart
[
{
"q": "CXCR4 AND 20-name menin-inhibitor list",
"hits": 65,
"read": 50,
"on_topic": 0,
"proceedings": 2
},
{
"q": "(CXCR4 OR CXCL12 OR SDF-1) AND the same list",
"hits": 69,
"read": 50,
"on_topic": 0,
"proceedings": 4
},
{
"q": "CXCR4 alone",
"hits": 68559,
"role": "operand control"
}
]nearest record
{
"pmid": "41743263",
"title": "Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups",
"venue": "HemaSphere",
"year": 2026,
"status": "TITLE-CHECKED, not opened"
}- Does PMID 41743263 include a surface-marker panel under menin inhibition? It is the one primary KMT2A-rearranged paper in the hit list.
- Do the deposited RNA-seq series under menin inhibitors - GSE260456 among them - contain CXCR4 transcript measurements? That would convert this from never-measured-in-print to measured-not-analysed with an accession, and is a desk job.
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.database
CXCR4 crossed with a 20-name menin-inhibitor list returns 65 full-text records and 69 with CXCL12 and SDF-1 added, against an operand of 68,559 for CXCR4; of the 50 read, 2 are congress abstract books and the remainder are review articles, none reporting a CXCR4 measurement under menin inhibition.
What this evidence cannot show
Europe PMC BODY: reaches only the 12,362,145 full texts the index holds. A congress abstract book is one document holding thousands of unrelated abstracts and matches almost any conjunction; across this beat's 18 fully-read intersections 83 of 321 records (25.9%, range 0-50%) are proceedings. Screening was at TITLE level unless a paper is listed as opened. 50 of 65 read; 15 not read. The receptor clause widening to CXCL12 and SDF-1 added only four records, which argues the ligand literature is not separately indexed here rather than that it was searched thoroughly. Judging 48 records as reviews was done from titles and journal names.
Evidence that argues against this (1)
- A CXCR4 flow-cytometry panel run alongside a menin-inhibitor experiment is precisely the kind of supporting measurement that appears in a figure with no mention in the body text, so even a full-text zero cannot bound it - rule 80's limit survives the move to full text for a surface-marker readout. The honest scope is 'no full text says so', not 'nobody measured it'. Europe PMC 2026
SURVIVES at full text: 65 records, 50 read, all reviews - a third independent confirmation after two clean abstract-level runs